Currently, the STING-targeted treatment is a candidate for anti-tumor immunotherapy and agents such as ADU-S100 (MIW815) (ClinicalTrials.gov, Identifier: NCT02675439), MK-1454 (NCT03010176), and E7766 (NCT04144140) have been approved for clinical trials to test their role in cancer progression in humans. Here, STING1 is linked to cancer.